We provide a wide range of antibiotic susceptibility testing services such as Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) tests in accordance with the guidelines issued by the Clinical and Laboratory Standards Institute using broth micro dilution, broth macro-dilution, disk diffusion and agar dilution methods.
Minimum Inhibitory Concentration (MIC)
The MIC testing services for New Chemical Entity (NCE) helps determine the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism under defined test conditions.
We use the MIC values to evaluate the activity of new antimicrobial agents and to determine the NCE’s susceptibilities of microorganisms. MIC is considered as the ‘gold standard’ for determining the susceptibility of organisms to antimicrobials and is therefore used to judge the performance of all other methods of susceptibility testing.
Cultured microbes are incubated with the NCE at various concentrations and measured for the results using agar dilution or broth dilution methodology to determine the MIC endpoint. Agar dilution involves incorporating different concentrations of the antimicrobial substance into agar medium followed by the application of a standardized number of cells to the surface of the agar plate. For broth dilution, we often determine it in 96-well micro titer plate format, where microorganisms are inoculated into a liquid growth medium in the presence of different concentrations of an antimicrobial agent. Growth is assessed after incubation for a defined period of time (16–20 hours).
Susceptibility testing is typically conducted using organisms that contribute to an infectious process warranting antimicrobial chemotherapy. Several microorganisms such as aerobic or anaerobic bacteria, yeasts can be tested based on the requirement.
Minimum Bactericidal Concentration (MBC)
The MBC testing services help determine the lowest concentration of an antimicrobial agent required to achieve bactericidal killing defined at 99.9% reduction in the initial inoculum. We chose it by sub-culturing broth dilution concentrations that inhibit the growth of a bacterial organism i.e. concentrations at and above the MIC. The broth dilutions are streaked onto agar surface and incubated for 24 to 48 hours. MBC is the lowest broth dilution of antimicrobial that prevents the growth of the organism on the agar plate. Failure of the organism to grow on the agar plate implies that all viable microorganisms have been eliminated.
Why Aurigene Pharmaceutical Services?
Submissions to the US FDA
Highly- qualified and experienced scientists
Audited by the US FDA with zero 483 in 2019
BSL-2 compliant microbiology lab
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Microbiology Testing
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read More
Accelerating Drug Discovery Through Innovative Partnerships
Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....
Read More
Physiochemical Characterization Services
Backed by our strong chemistry, we enable “Finger-print” protein structure and functional characterization for proteins from naked proteins to hyperglycosylated or derivatized proteins. ...
Read More
Expediting early development through innovative precision capsule filling technology
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...
Read More
Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridinesw
2012
A conceptually new three-component reaction was developed to construct a six-membered fused N-heterocyclic ring affording (pyrazolo)pyrimidines/pyridines as potential inhibitors of PDE4. The reaction is catalyzed by triflic acid in acetic acid in the presence of aerial oxygen. ...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.